Role of Thrombotic Vascular Risk Factors in Inflammatory Bowel Disease

2000 ◽  
Vol 18 (3) ◽  
pp. 161-167 ◽  
Author(s):  
I.E. Koutroubakis
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Vascular Risk Factors ◽  
Vascular Risk ◽  
Inflammatory Bowel

Thrombotic vascular risk factors in inflammatory bowel disease

2003 ◽  
Vol 124 (4) ◽  
pp. A190-A191
Author(s):  
Guillaume Geslin ◽  
Franck Brazier ◽  
Eric Bartoli ◽  
Bertrand Roussel ◽  
Jean-Paul Latrive ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Vascular Risk Factors ◽  
Vascular Risk ◽  
Inflammatory Bowel

scholarly journals Thrombotic vascular risk factors in inflammatory bowel disease.

Gut ◽  
1996 ◽  
Vol 38 (5) ◽  
pp. 733-737 ◽  
Author(s):  
M Hudson ◽  
A Chitolie ◽  
R A Hutton ◽  
M S Smith ◽  
R E Pounder ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Vascular Risk Factors ◽  
Vascular Risk ◽  
Inflammatory Bowel

Inflammatory Bowel Disease and the Emergency Department: Risk Factors for Repeated Visits and Role of CT Imaging

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S333-S334
Author(s):  
Lauren George ◽  
Jennifer Cahill ◽  
Fauzia Ullah ◽  
Brendan Martin ◽  
Nikiya Asamoah ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Emergency Department ◽  
Bowel Disease ◽  
Ct Imaging ◽  
Inflammatory Bowel

scholarly journals Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery

2020 ◽  
Vol 9 (7) ◽  
pp. 2115
Author(s):  
Alfredo Papa ◽  
Antonio Tursi ◽  
Silvio Danese ◽  
Gianludovico Rapaccini ◽  
Antonio Gasbarrini ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Venous Thromboembolism ◽  
Bowel Disease ◽  
Pharmacological Therapy ◽  
Increased Risk ◽  
Relevant Role ◽  
Inflammatory Bowel ◽  
The Individual

Patients with inflammatory bowel disease (IBD) have an increased risk of venous thromboembolism (VTE). Alongside the traditional acquired and genetic risk factors for VTE, patients with IBD have pathogenic and clinical peculiarities that are responsible for the increased number of thromboembolic events occurring during their life. A relevant role in modifying this risk in a pro or antithrombotic manner is played by pharmacological therapies and surgery. The availability of several biological agents and small-molecule drugs with different mechanisms of action allows us to also tailor the treatment based on the individual prothrombotic risk to reduce the occurrence of VTE. Available review articles did not provide sufficient and updated knowledge on this topic. Therefore, we assessed the role of each single treatment, including surgery, in modifying the risk of VTE in patients with IBD to provide physicians with recommendations to minimize VTE occurrence. We found that the use of steroids, particularly if prolonged, increased VTE risk, whereas the use of infliximab seemed to reduce such risk. The data relating to the hypothesized prothrombotic risk of tofacitinib were insufficient to draw definitive conclusions. Moreover, surgery has an increased prothrombotic risk. Therefore, implementing measures to prevent VTE, not only with pharmacological prophylaxis but also by reducing patient- and surgery-specific risk factors, is necessary. Our findings confirm the importance of the knowledge of the effect of each single drug or surgery on the overall VTE risk in patients with IBD, even if further data, particularly regarding newer drugs, are needed.

Risk Factors for Thromboembolic Complications in Inflammatory Bowel Disease: The Role of Hyperhomocysteinaemia

2005 ◽  
Vol 50 (2) ◽  
pp. 235-240 ◽  
Author(s):  
Bas Oldenburg ◽  
Bas A. C. Van Tuyl ◽  
René van der Griend ◽  
Rob Fijnheer ◽  
Gerard P. van Berge Henegouwen
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Thromboembolic Complications ◽  
Inflammatory Bowel

Microscopic colitis and the role of the specialist inflammatory bowel disease nurse: a clinical review

2021 ◽  
Vol 19 (9) ◽  
pp. 20-26
Author(s):  
Cathy Walsh
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Clinical Review ◽  
Bowel Disease ◽  
Activity Index ◽  
Microscopic Colitis ◽  
Nurse Specialist ◽  
Inflammatory Bowel

Microscopic colitis (MC) is an inflammatory bowel condition similar to but distinct from classical inflammatory bowel disease (IBD). Unlike ulcerative colitis and Crohn's disease, MC is predominately a self-limiting and treatable condition. It is characterised by colonic inflammation and symptoms of watery, non-bloody diarrhoea, alongside abdominal pain and weight loss, causing anxiety, fatigue and reduced quality of life. The prevalence of MC is 119 per 100 000 population and growing. Its aetiology and pathophysiology are poorly understood, but it is likely multifactorial, and possible risk factors include smoking and certain medications and autoimmune conditions. Diagnosis relies on endoscopic biopsy to identify intraepithelial lymphocytosis. Management and treatment begin with excluding possible risk factors and can include anti-diarrhoeal medications, bile acid binders and budesonide, which is highly effective at inducing and maintaining remission. Refractory disease is rare, but it may require biological medications or even surgery. Disease activity is monitored with the Hjortswang criteria and Microscopic Colitis Disease Activity Index. This narrative clinical review draws on recent guidelines and study data to explore the uncertain role of the clinical nurse specialist in caring for these patients.

scholarly journals P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S219-S220
Author(s):  
B Scrivo ◽  
C Celsa ◽  
A Busacca ◽  
E Giuffrida ◽  
R M Pipitone ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Extraintestinal Manifestations ◽  
Previous Surgery ◽  
Inflammatory Bowel ◽  
Traditional Risk Factors

Abstract Background Prevalence of NAFLD has recently been reported increased in inflammatory bowel disease (IBD) with conflicting results due to heterogeneity of published studies, especially in the diagnostic definition of NAFLD. The increased risk of NAFLD might be related to traditional risk factors but also to IBD-related factors. The role of genetic markers has been addressed only in one study. The aim of our study has been to assess the prevalence of NAFLD and fibrosis in a homogeneous cohort of patients with IBD, assessing the role of metabolic, disease-related and genetic factors. Methods the diagnosis of NAFLD was based on transient fibroelastometry findings (CAP ≥288 dB/m) and HSI (Hepatic Steatosis Index). Demographic data, traditional risk factors for NAFLD (BMI, lipid profile), comorbities, laboratory tests, disease features (type of IBD, duration, extent, extraintestinal manifestations, relapses/year, disease activity, previous surgery, therapy) were registered in a dedicated database. PNPLA3 rs738409 C>G single nucleotide polymorphism, encoding for I148M protein variant, was investigated by Taqman assay. Results 208 consecutive patients were enrolled: 120 males, 121 Crohn’s disease, 87 ulcerative colitis, mean age 46,4 ± 15,2 years. 26 patients (12,5%) were on steroids, 121 on biologics. The prevalence of NAFLD was 20,7% with mean HSI being 38,3 ± 4,7.On univariate analysis, patients with NAFLD were older (54,6 ± 11,1 years), had higher BMI (28,1 ± 3,9 vs. 24,1 ± 3,8), had more frequently hypertension and high level of LDL and tryglicerides. No significant difference was found as far as concerns gender, number of relapses, extraintestinal manifestations, disease activity and duration and ongoing therapy. Medium stiffness value was higher in patients with NAFLD (6,4 ± 2,4 vs. 4,8 ± 2,2 KPa). CG phenotype of PNAPL3 was more frequent among NAFLD patients, though the result was not significant. On multivariate analysis age, BMI, previous surgery and level of stiffness > 6,9 kPa were independently related to NAFLD. Conclusion This single center cross-sectional study shows that, by using transient elastography, the prevalence of NAFLD in IBD is 20,7% with a significantly increase of liver stiffness and development of fibrosis. NAFLD was related to traditional risk factors (age, BMI, lipid profile) and to previous ileal resection, the last probably due to changes of gut microbiota. Neither intestinal inflammation and drugs nor genetic testing for PNAPL3 seem to be related to the development of NAFLD. Longitudinal studies are warranted to assess the progression of fibrosis and the role of therapeutic interventions.

The role of osteopontin (OPN/SSP1) gene variants in inflammatory bowel disease

2009 ◽  
Vol 47 (09) ◽  
Author(s):  
J Glas ◽  
J Seiderer ◽  
HP Török ◽  
B Göke ◽  
T Ochsenkühn ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Gene Variants ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document